Table of Contents
ISRN Pediatrics
Volume 2012, Article ID 436046, 6 pages
http://dx.doi.org/10.5402/2012/436046
Clinical Study

Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients

1Department of Nephrology and Rheumatology, University Medical Center Göttingen, Robert-Koch Straβe 40, 37075 Göttingen, Germany
2Department of Medical Statistics, University Medical Center Göttingen, 37075 Göttingen, Germany
3Institute for Applied Research and Clinical Trials GmbH (IFS) and Georg August University Göttingen, 37075 Göttingen, Germany

Received 4 March 2012; Accepted 11 April 2012

Academic Editors: R. Bhimma, T. V. Brogan, and S. Fanconi

Copyright © 2012 Oliver Gross et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Oliver Gross, Tim Friede, Reinhard Hilgers, et al., “Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients,” ISRN Pediatrics, vol. 2012, Article ID 436046, 6 pages, 2012. https://doi.org/10.5402/2012/436046.